Biotech Values

[mcbio]

Late-Stage Products Looking for a Home

Criteria for inclusion:
a) Program has completed phase-2b or later and is non-partnered; AND
b) Company lacks the financial resources to commercialize the product on its own.

Edits: Added two ARYX entries.

 
  Company  Product     Phase   Indication (notes)   
  =======  =======     =====   ==================   
  ARNA     Lorcaserin  NDA     Obesity   
  ARYX     Budiodarone 2B      Atrial Fibrillation 
  ARYX     Tecarfarin  3       Oral anticoagulant (failed initial Phase 3) 
  BPAX     Libigel     3       Female Sexual Desire Disorder   
  DYAX     Kalbitor    US app  acute hereditary angioedema (seeking x-US partner)   
  HNAB     Marqibo     2B      ALL (ENZN failed accelerated approval in NHL)   
  JAV      Dyloject    NDA     Post-op pain (approved in UK)   
  JAV      Ketamine    3       Acute pain   
  OREX     Contrave    NDA     Obesity   
  OXGN     Zybrestat   3       Anaplastic thyroid cancer   
  MNKD     Afrezza     BLA     Diabetes (CRL rec’d 3/15/10)   
  Pharming Rhucin      BLA     HAE (rejected and resubmitted in EU)   
  SOMX     Silenor     apprvd  Insomnia (low dose of generic doxepin)   
  SVNT     Krystexxa   BLA     Gout (response to CRL submitted 3/30/10)   
  VVUS     Qnexa       NDA     Obesity

Procedure for Updating Table

1. Copy the text in this post into a word processor.

2. Using a monospace font (e.g. Courier) to facilitate tabular
alignment, make your additions and modifications, inserting
them in the table in alphabetical order. NOTE: use spaces
rather than tab characters.

3. Add a brief note in the “Edits:” line atop the table to
describe your changes.

4. Insert the iHub formatting directives: Put [ pre ] at the
beginning of the table without the surrounding spaces, and
put [ /pre ] at the end of the table without the surrounding
spaces.

5. Post your text as a reply to this message.

Thank you for your cooperation.